1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This is a Notice of Funding Opportunity (NOFO) for a Limited Competition that will invite application(s) from eligible organization(s) to apply. Please see Section III. Eligibility for additional information. In accordance with NIH standard peer-review processes, the application(s) will be peer-reviewed, and only meritorious application(s) will be considered for funding. This NOFO requests limited competition applications for a 3-year extension of the COPE-AKI clinical trial consortium, which includes three clinical centers (CCs) and one scientific and data research center (SDRC), to fully meet the enrollment targets, complete participant follow-up, and provide resources for data analysis and dissemination of study findings. There is currently no standard of care for patients after hospitalization with acute kidney injury (AKI). Successful completion of the COPE-AKI study will provide key insights that are expected to directly inform improved clinical management strategies and the development of standard of care for Stage 2 and 3 AKI survivors.
Funding Opportunity Number: RFA-DK-27-125. Assistance Listing: 93.847. Funding Instrument: CA. Category: HL. Award Amount: $1.9M total program funding.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Eligible applicants: Others (see text field entitled Additional Information on Eligibility for clarification). Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.As this NOFO is a Limited Competition, only the current recipients under RFA-DK-20-011 are eligible to apply under this announcement.As this NOFO is a limited competition opportunity, only the institutions that are the principal employer of the Program Director/Principal Investigator of the original COPE-AKI Participating Clinical Centers and the COPE-AKI Scientific Data Research Center are eligible to apply in response to this NOFO.Foreign Organizations/International Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are not allowed. Confirm the full requirements in the official notice before applying.
The current listing shows $1.9M total program funding. Verify award ceilings, matching requirements, and allowable costs in the official notice.
Applications for Limited Competition for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Clinical Centers (U01 Clinical Trial Required) are due November 6, 2026. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
Yes — Limited Competition for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Clinical Centers (U01 Clinical Trial Required) is offered by National Institutes of Health and this listing comes from Grants.gov, an official U.S. federal source. Federal applications generally require registrations (for example SAM.gov or an agency submission portal), so allow extra lead time.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
PA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read articlePA-27-034, PA-27-035 and PA-27-036 replace the institute-specific R25 announcements that research education programs have been built around for a decade. NCI, NIDA and NIGMS have already expired theirs early. Here is what the consolidation actually changes: an 8% indirect cost ceiling, a US-citizens-and-permanent-residents participant rule, a cooperative agreement variant that only exists on one of the three, and no clinical-trial-allowed companion anywhere.
Read article